| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1087: Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen |
|
Medicine details |
|
| Medicine name | betula verrucosa (Itulazax 12 SQ-Bet®) |
| Formulation | Sublingual lyophilisate |
| Reference number | 3859 |
| Indication | For use in adults and children (5 years or older) for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. ITULAZAX is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE) |
| Company | ALK-Abello Ltd |
| BNF chapter | Immunological products & vaccines |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/07/2025 |
| NICE guidance | |